Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock

Key Points

• CEO Eric Lefkofsky sold 166,250 shares on Jan. 28 at an average price of $65.56 for about $10.9M, reducing his stake by 1.83% to 8,941,533 shares valued near $586.2M.
• Tempus shares fell roughly 5.8% to $59.82 on above-average volume (6.35M vs. 5.56M), reflecting continued volatility with a 12‑month range of $36.22–$104.32 and a beta of 5.22.
• The company reported EPS of ($0.11) and revenue of $334.2M (up 84.7% YoY), but remains unprofitable; analysts are mixed with a consensus "Hold" and a $87.20 price target.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the business's stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the transaction, the chief executive officer directly owned 8,941,533 shares of the company's stock, valued at approximately $586,206,903.48. This trade represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tempus AI Trading Down 5.8%

Shares of Tempus AI stock traded down $3.69 during trading hours on Friday, hitting $59.82. The company's stock had a trading volume of 6,347,981 shares, compared to its average volume of 5,555,039. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The firm has a fifty day moving average of $68.76 and a 200-day moving average of $73.88. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of -50.27 and a beta of 5.22.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to analysts' expectations of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business's revenue was up 84.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. Research analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. BTIG Research increased their target price on Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Tuesday, November 25th. Piper Sandler cut their price objective on shares of Tempus AI from $105.00 to $80.00 and set a "neutral" rating for the company in a research report on Tuesday, November 11th. Canaccord Genuity Group reduced their price objective on Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a research report on Monday, December 22nd. Morgan Stanley raised their price target on shares of Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a report on Monday, December 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Tempus AI in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $87.20.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $25,000. Concord Wealth Partners raised its holdings in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company's stock worth $26,000 after purchasing an additional 308 shares during the period. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the third quarter valued at about $26,000. GAMMA Investing LLC bought a new position in Tempus AI during the third quarter worth about $28,000. Finally, Allworth Financial LP boosted its position in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company's stock valued at $29,000 after acquiring an additional 450 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.